{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=21",
    "query": {
      "condition": "Metabolic Abnormalities",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 2423,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T22:40:59.126Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01728064",
      "title": "Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EPI-743 400 mg",
          "type": "DRUG"
        },
        {
          "name": "EPI-743 200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2012-12-31",
      "completion_date": "2016-02-29",
      "has_results": false,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728064"
    },
    {
      "nct_id": "NCT00167206",
      "title": "Stem Cell Transplantation for Fanconi Anemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fanconi Anemia"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymic Shielding During Radiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Body Irradiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide, Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Day to 18 Years"
      },
      "enrollment_count": 16,
      "start_date": "2004-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-26",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167206"
    },
    {
      "nct_id": "NCT07667387",
      "title": "Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urea Cycle Disorders",
        "Carbamoyl-Phosphate Synthase I Deficiency"
      ],
      "interventions": [
        {
          "name": "LNP.UCD.ABE",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rebecca Ahrens-Nicklas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Hours",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "24 Hours to 5 Years"
      },
      "enrollment_count": 7,
      "start_date": "2026-08-07",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667387"
    },
    {
      "nct_id": "NCT00031421",
      "title": "Neonatal CMV-Ganciclovir Follow-up Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "9 Years to 14 Years"
      },
      "enrollment_count": 8,
      "start_date": "2001-09",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2011-08-12",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031421"
    },
    {
      "nct_id": "NCT03387709",
      "title": "UCSD Get Fit, Be Fit Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Pistachio-enriched diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "General dietary guidance diet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-04-04",
      "completion_date": "2019-10-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03387709"
    },
    {
      "nct_id": "NCT01519687",
      "title": "Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout"
      ],
      "interventions": [
        {
          "name": "levotofisopam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-01",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-01-27",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519687"
    },
    {
      "nct_id": "NCT05586971",
      "title": "Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout",
        "Hyperuricemia",
        "Gout Flare",
        "Tophi"
      ],
      "interventions": [
        {
          "name": "Tigulixostat",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LG Chem",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 2202,
      "start_date": "2023-03-30",
      "completion_date": "2025-05-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 124,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05586971"
    },
    {
      "nct_id": "NCT03392896",
      "title": "Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "DCR-PHXC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2017-12-06",
      "completion_date": "2019-11-19",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03392896"
    },
    {
      "nct_id": "NCT05119686",
      "title": "Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout",
        "Arthritis, Gouty",
        "Hyperuricemia",
        "Gout Chronic"
      ],
      "interventions": [
        {
          "name": "AR882 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "AR882 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arthrosi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 140,
      "start_date": "2021-11-16",
      "completion_date": "2022-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Sun City, Arizona • Tucson, Arizona + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119686"
    },
    {
      "nct_id": "NCT02574286",
      "title": "Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gaucher Disease"
      ],
      "interventions": [
        {
          "name": "Velaglucerase alfa",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 21,
      "start_date": "2016-06-29",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-02-01",
      "last_synced_at": "2026-10-28T22:40:59.126Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574286"
    }
  ]
}